Compare Extra Space Storage, Inc. (EXR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Extra Space Storage, Inc. trades at $133.26 (market cap $28.12B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Extra Space Storage, Inc. is far larger — about 13.1× Recursion Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EXR | RXRX | |
|---|---|---|
Market Cap | $28.12B | $2.14B |
Volume | 2,595,579 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $6.79 |
52-Week Low | $126.67 | $2.84 |
Typical Hold Time | 108 Days | 22 Days |
Enterprise Value | $41.84B | $1.66B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $131.70, down 1.64% with a bearish technical signal. The company maintains strong fundamentals with consistent earnings beats, 27.79% net margin, and $974M net income. Revenue growth has been steady from $1.9B in 2022 to $3.4B in 2025. Analyst consensus is split with 14 Buy and 14 Hold ratings, targeting $158.33 average price. Recent leadership transition to Noah Springer as CEO effective January 2027 adds strategic focus.
EXR presents a balanced risk-reward profile with solid operational performance offset by technical weakness. The REIT's scale, 94.2% occupancy, and dividend yield support long-term value, though current price action suggests near-term pressure. Debt levels at 46.63% debt-to-asset ratio require monitoring amid rising interest rates. Upside potential exists if Q3 2026 earnings beat expectations on October 27.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
